ArgoCap® for APC: First multicenter experience across GI indications

First multicenter clinical study confirms the feasibility of ArgoCap® for APC treatment across diverse GI indications, with a high technical success rate and low complication rate

Key findings

• 87% technical success rate (defined as reaching the target lesion with macroscopically complete ablation)
• 98% of procedures achieved more-than-subtotal ablation (>90% of target region)
• Applicable across upper and lower GI tract: esophagus (69%), stomach (16%), rectum (15%)
• Low complication rate: 2% (ulceration with subsequent bleeding)

Study details

• First multicenter clinical study at 3 German expert centers (January 2022 – May 2025)
• 54 APC procedures performed with ArgoCap®; hybrid-APC was used in 7% of cases
• Aim: Evaluation of clinical feasibility, handling, technical success rate, and safety of ArgoCap® for various GI indications
• Indications: Barrett mucosa, ectopic gastric mucosa, gastric angiectasia, gastric antral vascular ectasia (GAVE), radiation proctitis, and others
• Median lesion size: 11 mm (range 2–60 mm)
• Median ablation duration: 8 minutes (range 2–15 min)
• Median total procedure duration: 25 minutes (range 8–75 min)

Mueller J, Küllmer A, Schmidt A, Schiemer M, Thimme R, Walter B. Die ArgoCap: Erste multizentrische klinische Erfahrungen / The ArgoCap: Initial multicenter clinical experience. Presentation at DGE-BV 2026 (25-27 Mar), Leipzig, Germany.

This content is intended exclusively for healthcare professionals. Please refer to the instructions for use and note country-specific approvals and indications.